Video Reports

Richard D. Carvajal, MD: We’ve had 2 dedicated clinical trials now for the uveal melanoma patient population, the 102 trial and then the 202 trial.

Richard D. Carvajal, MD: Let’s shift gears to tebentafusp, an immunotherapy where there is clear success. I wonder if you can describe for the audience how this drug works? What’s its mechanism?

Richard D. Carvajal, MD: You’re right, this is reminiscent to me of the ipilimumab experience where you get the survival benefit despite the low response rate.

Hussein A. Tawbi, MD, PhD, the deputy chair of the Department of Melanoma Medical Oncology, Division of Cancer Medicine; the director of Melanoma Clinical Research and Early Drug Development…